Also known as: obstructive HCM
Obstructive hypertrophic cardiomyopathy is a form of hypertrophic cardiomyopathy in which septal thickening narrows the left ventricular outflow tract, causing dynamic obstruction, symptoms, and risk of arrhythmia.
Mavacamten significantly reduces heart obstruction in adolescents with hypertrophic cardiomyopathy, with patients experiencing a 48.5 mm Hg drop in blockage compared to minimal change in placebo groups. The drug also lowered blood markers indicating heart damage and showed promise in slowing disease progression. Separate real-world data confirms mavacamten's effectiveness as monotherapy across diverse patient populations.
The European Commission approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy in adults, completing global regulatory approvals following FDA and China NMPA clearances. First European launch planned in Germany in Q2 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07023341 |
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT07021976 |
A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy |
RECRUITING | PHASE3 |
| NCT06856265 |
Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy |
NOT_YET_RECRUITING | NA |
| NCT06598995 |
Myocardial Bridging in Obstructive Hypertrophic Cardiomyopathy |
COMPLETED | |
| NCT06551129 |
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos |
RECRUITING | |
| NCT06516068 |
A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06368037 |
Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy |
NOT_YET_RECRUITING | NA |
| NCT06354556 |
Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects |
COMPLETED | PHASE1 |
| NCT06224621 |
Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy |
RECRUITING | NA |
| NCT06211595 |
Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy |
ACTIVE_NOT_RECRUITING | NA |
